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THYROID CANCER AND NODULES
The Most Commonly Occurring Papillary Thyroid Cancer
in the United States Is Now a Microcarcinoma
in a Patient Older than 45 Years
David T. Hughes,1 Megan R. Haymart,2 Barbra S. Miller,3 Paul G. Gauger,3 and Gerard M. Doherty3
Background: The incidence of papillary thyroid cancer (PTC) is growing at a faster rate than any other malig-
nancy. However, it is unknown what effect age is having on the changing PTC incidence rates. With the goal of
understanding the role of age in thyroid cancer incidence, this study analyzes the changing demographics of
patients with PTC over the past three decades.
Methods: This was a retrospective evaluation of the incidence rates of PTC from 1973 to 2006 reported by the
National Cancer Institute’s Surveillance, Epidemiology, and End Results database.
Results: From 1973–2006 the age group most commonly found to have PTC has shifted from patients in their 30s
to patients in the 40–50-year-old age group. In 1973 60% of PTC cases were found in patients younger than 45,
and the majority of cases continued to occur in younger patients until 1999. After 1999 PTC became more
common in patients older than 45 years, and in 2006, 61% of PTC cases were in patients older than 45 years.
From 1988 to 2003 there has been an increasing incidence of all sizes of PTC in all age groups with the largest
increase in tumors <1 cm in patients older than 45. Forty-three percent of tumors in patients older than 45 are
now <1 cm, whereas only 34% are <1 cm in patients younger than 45. Of the nearly 20,000 thyroid cancer cases
in 2003, 24% were microcarcinomas in patients over the age of 45.
Conclusions: The incidence of PTC is increasing disproportionally in patients older than 45 years. The number of
PTC tumors smaller than 1 cm is increasing in all age groups, and now the most commonly found PTC tumor in
the United States is a microcarcinoma in a patient older than 45 years. These changing patterns relating age and
incidence have important prognostic and treatment implications for patients with PTC.
Introduction
The American Cancer Society estimates the number ofnew thyroid cancer cases in the United States to reach
37,200 with 1630 deaths in 2009 (1). Several population-based
studies have demonstrated increasing rates of thyroid cancer
over the past several decades with the largest increase seen in
small tumors without significant changes in mortality rates
(2–5). Speculation as to the reason for the increasing incidence
has ranged from increased detection due to more frequent
use of imaging studies, more thyroid nodule biopsies, and
increased environmental exposure to diagnostic imaging ra-
diation and carcinogenic toxins (2,6–11). Characterizing the
subset of patients within whom the rising rates of thyroid
cancer is most apparent is important to understanding the
etiology of this rise in incidence. Using the National Cancer
Institute’s Surveillance, Epidemiology, and End Results
(SEER) database, this study evaluates the changing demo-
graphics of papillary thyroid cancer (PTC) over the past 30
years with respect to age and tumor size.
Materials and Methods
This was a retrospective analysis of thyroid cancer inci-
dence data obtained from the National Cancer Institute’s
SEER 17 registry. Based on United States census data from
2000, this registry has a total population of *74 million
people or 26% of the United States population. New cases of
PTC were selected from the registry using the International
Classification of Disease for Oncology codes (8050, 8052, 8130,
8260, 8340–8344, 8450, 8452) based on the American Joint
Committee on Cancer (AJCC) staging system. All subtypes of
PTC were included in the analysis, including, but not limited
to, tall cell, columnar cell, diffuse sclerosing, insular, and
follicular variant of papillary carcinoma to obtain a complete
evaluation of the incidence of papillary cancer. From 1973 to
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2006 patient demographic data and, starting in 1988, primary
thyroid tumor characteristic data were analyzed using the
SEERStat 6.5.2 program provided by the National Cancer
Institute. Tumor size was determined using the SEERStat re-
code EOD-88, 3rd edition. Estimated U.S. incidence rates were
calculated using the 2000 U.S. census estimated total popu-
lation as described previously (2,5). Recognizing the impor-
tance of age in the AJCC staging system for thyroid cancer,
cases of PTC were divided by age group older and younger
than 45 years. Statistical differences between groups were
determined with the Student’s t-test or chi-squared test
for trend with a p-value <0.05 considered statistically sig-
nificant.
Results
From 1973 to 2006 there were 68,803 recorded new cases
of PTC in the SEER 17 registry equating to an estimated
262,000 cases in the United States over this 33-year period.
There was a steady increase in the incidence of PTC during the
study period, both in the older and younger than 45 age
groups (Fig. 1a). Beginning in 1999 there was a significantly
FIG. 1. (a) New cases and
(b) percent of new cases
of papillary thyroid cancer
(PTC) per year in patients
younger than or older than
45 years in the United States
from 1973–2006.
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larger increase in the number of new cases in patients older
than 45 ( p¼ 0.002) (Fig. 1a). Until 1999 the majority of new
PTC cases occurred in patients younger than 45; however,
after 1999 the majority of cases occurred in patients older than
45 (Fig. 1b). Over the 7 years from 1999 to 2006 there was a
steady divergence in the age distribution of newly diagnosed
PTC, and in 2006, 61% of cases occurred in patients older than
45 (Fig. 1b).
When the number of new PTC cases were compared over
the last 20 years the age group with the most new cases shifted
from patients aged 25–34 years to patients aged 45–54 years
(Fig. 2a, b). Although all age groups had an increase in new
PTC cases, the largest increase occurred in patients aged 45–54
with an*10-fold increase over the past 20 years (Fig. 2a, b). In
1986 the most cases of PTC occurred in the 25–34-year-old age
group, whereas in 2006 the majority of cases were found in the
45–54-year-old age group (Fig. 2a, b).
Since 1988, when SEER began collecting data on tumor size,
the incidence of all sizes of PTC primary tumors has increased
across all age groups. In patients<45 years of age the number
FIG. 2. (a) New cases and
(b) percent of new cases of
PTC by patient age in the
United States in 1986 and
2006.
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of newly diagnosed small (0.1–1 cm) and mid-sized (1.1–4 cm)
tumors has been consistently higher than that of large (>4 cm)
tumors (Fig. 3a). In patients older than 45, the number of small
tumors has increased at a faster rate than both mid-sized and
large tumors ( p 0.001) (Fig. 3b). PTC rates were similar for
small and mid-sized tumors in the younger age group and for
mid-sized tumors in the older age group at around 2500 new
cases in the United States in 2003 (Fig. 3a, b). The most com-
mon type of PTC in 2006 was a small tumor in a patient older
than 45 with an estimated 4672 cases in the United States
(Fig. 3b). There was an increase in the percentage of PTC
tumors classified as small (0.1–1 cm) and large (>4 cm) in both
age groups and a decrease in the percentage of mid-sized (1.1–
4 cm) tumors when comparing case numbers in 1988–2003
(Fig. 4a, b). In 2003, 43% of new tumors in older patients were
1 cm or less, whereas only 34% were 1 cm or less in patients
younger than 45 (Fig. 4a). In 2003 there were an estimated
19,663 new cases of PTC in the United States, and of these 4671
(24%) were primary tumors <1 cm in size in patients older
than 45.
FIG. 3. New cases PTC per
year in the United States
from 1988 to 2003 by size of
primary tumor and patient
age younger (a) or older
(b) than 45 years.
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Discussion
This study demonstrates the changing age demographic of
PTC patients in the United States over the past 30 years.
Several studies have demonstrated the increasing incidence
of all types of thyroid cancer based on population database
analyses (2–4). Patient demographics and tumor characteris-
tics have also been further evaluated using these datasets
(5,12,13). To our knowledge, no other study has demonstrated
the important shift in age group that has occurred in con-
junction with the exponential growth of PTC incidence over
the past three decades in the United States. These trends are
not due to the aging of SEER population, as the distribution of
patient age has remained constant since the inception of the
program in 1973 (14). The majority of patients with PTC are
now older than 45 years, which has important implications for
prognosis and adjuvant treatment as reflected by the key role
that age plays in the AJCC staging system for differentiated
thyroid cancer. In the 1980s the majority of PTC cases
occurred in patients in their late 20s and early 30s; thus, the
majority of patients with PTC could only be classified as stage
I or II by the AJCC system. However, by 2006 patients in their
late 40s and early 50s had the highest rates of PTC, meaning
that more patients with larger tumors, lymph node involve-
ment, or metastatic disease would be classified as stage III or
IV. This shift of stage will have important implications for
not only prognosis, but also adjuvant radioactive iodine
treatment after thyroidectomy based on the most recent
American Thyroid Association guidelines (15,16). Several
studies using population databases have demonstrated no
change in thyroid cancer mortality rates despite the increasing
prevalence and treatment of smaller primary tumors (2,5). The
aging patient population with the shift toward a higher AJCC
stage and thus higher rates of predicted mortality may play a
role in current and future mortality rates.
Analysis of tumor characteristics in this study showed that
the discovery of small tumors (<1 cm) increased at the fastest
rate in the older patient population with almost half of all
tumors now classified as microcarcinomas. The most com-
mon patient with PTC in the United States is now older than
45 with a primary tumor <1 cm, whereas 20 years ago that
patient would have been younger than 45 with a tumor
1–2 cm. Nearly a quarter of all PTC cases are now micro-
carcinomas in a patient older than 45 and these patients are
the main contributors to the rising incidence of PTC demon-
strated in population-based studies. These findings raise
many questions as to their etiology and implications for pa-
tient prognosis and treatment. Several studies have demon-
strated the relative increased incidence in small primary
tumors across all age groups (2,5). Our study demonstrates
that the increase in small tumors is occurring primarily in the
older patient population, whereas tumor size distribution has
remained relatively constant in the younger patient popula-
tion. When the rates of small tumors rise in a select group of
patients, it is because of new disease (potentially secondary
to environmental exposure), lead- or length-time bias, or over-
diagnosis of indolent disease (17). Given the 10%–36%
frequency of occult PTC on thorough autopsy studies, over-
diagnosis of indolent disease in the older patient population
who are more likely to have imaging studies performed is a
reasonable explanation (18,19). Therefore, we speculate that
one reason for the increased rates of small tumors is the in-
creasing use of imaging studies and subsequent discovery of
incidental thyroid nodules in the older patient population.
Another explanation may be the increasing utilization of near-
total thyroidectomy and total thyroidectomy in the treatment
of benign thyroid disease and PTC with subsequent increased
recognition of incidental microcarcinomas in surgical speci-
mens (20). The ATA guidelines do not recommend routine
biopsy of nodules <1 cm unless there are concerning features
(15). This would suggest that many of these microcarcinomas
are only recognized on thorough histologic analysis of sur-
gical specimens and that they are not the initial indication
for thyroidectomy. These possible explanations, however,
would not explain the increasing number of large tumors in
all age groups, suggesting that there are multiple contributing
factors.
The shift to older age groups and the increasing rate of
microcarcinomas may be contradictory in their implications
on prognosis and treatment of this patient subgroup. Despite
the potential for shift of stage because of older age, the ma-
jority of tumors in this older population are small and carry a
low risk of local invasion, lymph node metastasis, or distant
metastatic disease (21). Therefore, the majority of older
patients will likely remain stage I by AJCC classification.
Additionally, the minimal clinical significance of micro-
carcinomas may mean that treatment of these tumors will
FIG. 4. Percent of new PTC cases in the United states in
1988 and 2003 by size of primary tumor and patient age
younger (a) or older (b) than 45 years.
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provide minimal to no benefit in terms of survival, recurrence,
or risk of progression to locally advanced disease in individ-
ual patients or the population as a whole (18,19,21). Therefore,
it is unlikely that the increasing incidence of papillary mi-
crocarcinoma in the older patient population will have a sig-
nificant impact on overall patient outcomes.
The limitations of this study include data collection meth-
ods and analysis of the SEER patient registry, which includes
the possibility of underreporting patients treated for PTC and
the lack of standardization of histological description and
diagnosis. Another limitation is the use of the 2000 U.S. census
data in the relative calculation of incidence rates due to the
continued expansion and changing demographics of the U.S.
population, which will be reflected in the upcoming 2010
census results. The SEER database also does not include in-
formation on the patient factors and the detection method at
the time of initial diagnosis of thyroid cancer, which would be
valuable in further evaluating factors influencing the chang-
ing incidence rates.
In summary this 30-year population-based study demon-
strates a disproportional increase in PTC rates in patients
older than 45 with small (<1 cm) primary tumors. Nearly a
quarter of all PTC patients are now patients older than 45
years with microcarcinomas. The etiology of this age shift
may involve the increased use of imaging studies and treat-
ment of incidentally noted thyroid nodules for which further
studies are required.
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